SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,122.53 |
| Enterprise Value ($M) | 798.94 |
| Book Value ($M) | 315.34 |
| Book Value / Share | 2.01 |
| Price / Book | 3.56 |
| NCAV ($M) | 298.40 |
| NCAV / Share | 1.90 |
| Price / NCAV | 3.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.49 |
| Return on Assets (ROA) | -0.77 |
| Return on Equity (ROE) | -2.12 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.59 |
| Current Ratio | 10.66 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 440.99 |
| Assets | 457.94 |
| Liabilities | 142.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 63.72 |
| Operating Income | -171.78 |
| Net Income | -193.51 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -134.68 |
| Cash from Investing | -1.29 |
| Cash from Financing | 332.11 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Opaleye Management Inc. | 2.76 | -28.46 | |
| 13G | Avoro Capital Advisors LLC | 7.90 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 8.70 | 76.96 | |
| 13G/A | Vanguard Group Inc | 5.37 | 0.00 | |
| 13G/A | BlackRock, Inc. | 7.30 | 0.00 | |
| 13D/A | Summer Road Llc | 9.40 | 6.93 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 820,633 | 2,519,049 | 32.58 | |
| 223,462 | 995,381 | 22.45 | |
| 191,240 | 734,497 | 26.04 | |
| 162,562 | 780,587 | 20.83 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NRIX – Nurix Therapeutics, Inc. | NTLA – Intellia Therapeutics, Inc. |
| OCS – Oculis Holding AG | OKUR – OnKure Therapeutics, Inc. |
| OMER – Omeros Corporation |